Recent news on Rivastigmine Tartrate

Potential Of Exelon® Patch As Promising Treatment Approach For ...  -  Apr 24, 2007
Medical News Today (press release),Exelon (rivastigmine tartrate) is a dual cholinesterase inhibitor that is already approved in oral form in many countries for the treatment of mild to

First and Only Treatment Now Available for Mild-to-Moderate ...  -  Feb 16, 2007
PharmaLive.com (press release),EXELON(r) (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. EXELON(r) (rivastigmine tartrate) is

Medialink Features: First and Only Treatment Now Available for ...  -  Feb 15, 2007
Earthtimes.orgFortunately, the US Food and Drug Administration (FDA) recently approved Exelon(R) (rivastigmine tartrate) for the treatment of mild-to-moderate Parkinson's

After the Diagnosis: Managing Parkinson’s Disease  Aug 15, 2006
Earlier, this year, Rivastigmine tartrate (Excelon) became the first drug to be approved by the FDA for the treatment of mild to moderate dementia in PD. ... -ITP.net

VIDEO from Medialink: FDA Approves First Drug to Help Patients ...  Aug 10, 2006
The US Food and Drug Administration (FDA) has approved Exelon (rivastigmine tartrate) for the treatment of mild to moderate Parkinson's disease dementia ... -Genetic Engineering News



UPDATE 1-Novartis drug works for Parkinson's-FDA staffer  16 May 2006
Exelon, known generically as rivastigmine tartrate, was approved in 2000 to improve memory and thinking in Alzheimer's patients. ... - Reuters

Peripheral and Central Nervous System Drugs Advisory Committee  May 12, 2006
The committee will discuss supplemental new drug application (NDA) 20823, SE1-016, EXELON (rivastigmine tartrate) Capsules (1.5 milligrams (mg), 3.0 mg, 4.5 mg ... - FDA.gov





International Approvals: Exelon, VESIcare, Plavix  Mar 10, 2006
March 10, 2006 — The European Commission has approved a new indication for rivastigmine tartrate capsules and oral solution, allowing their use for the ... - Medscape (subscription)

Exelon granted EU marketing authorization as first treatment for ...  Mar 8, 2006
BASEL, SWITZERLAND -- March 8, 2006 -- Novartis announced today that Exelon® (rivastigmine tartrate) has been granted European marketing authorization by the ... - DG News

Exelon® Granted EU Marketing Authorization As First Treatment For ...  Mar 8, 2006
Novartis announced today that Exelon® (rivastigmine tartrate) has been granted European marketing authorization by the European Commission for the symptomatic ... - Medical News Today

European Union's CHMP Recommends Approval of Exelon (Rivastigmine ...  Jan 30, 2006
Medicinal Products for Human Use (CHMP) recommending that the European Commission grant a marketing authorization for Exelon® (rivastigmine tartrate) for the ... - DG News

CHMP adopts positive opinion recommending approval of Exelon? as ...  Jan 30, 2006
Medicinal Products for Human Use (CHMP) recommending that the European Commission grant a marketing authorization for Exelon? (rivastigmine tartrate) for the ... - WebWire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional